This Month in Business
The FDA approves pre-filled ranibizumab syringe, HOYA extend global reach, and CZM announce new appointment
- The FDA have approved Genentech’s pre-filled ranibizumab 0.5 mg syringe for the treatment of patients with wet age-related macular degeneration and macular edema after retinal occlusion. The syringe is expected to be available in early 2017.
- Envisia Therapeutics has released interim results from its ongoing 12 month Phase II study assessing a single administered dose of extended-release travoprost in five patients with glaucoma. Results demonstrate a 26 percent decrease in IOP nine months after administration.
- The FDA have approved Genentech’s pre-filled ranibizumab 0.5 mg syringe for the treatment of patients with wet age-related macular degeneration and macular edema after retinal occlusion. The syringe is expected to be available in early 2017.
- Envisia Therapeutics has released interim results from its ongoing 12 month Phase II study assessing a single administered dose of extended-release travoprost in five patients with glaucoma. Results demonstrate a 26 percent decrease in IOP nine months after administration.
- Allegro Ophthalmics has announced topline results from its Phase IIb DEL MAR trial evaluating ALG-1001 (Luminate versus bevacizumab monotherapy in patients with diabetic macular edema. Both the primary and secondary endpoints (non-inferiority to bevacizumab in best-corrected visual acuity and mean change in central macular thickness, respectively) were met at 20 weeks.
- HOYA announced an agreement to acquire Performance Optics and its subsidiaries VISION EASE and Daemyung Optical, expanding the Japanese company’s global reach.
- Abbott announced Q3 2016 sales of $5.3 billion. Sales for medical optics totaled $296 million – an increase of four percent on an operational basis which the company attributed to cataract products in their premium IOL segment. Johnson & Johnson is expected to complete acquisition of Abbot Medical Optics in early 2017.
- Novaliq has appointed Christian Roesky as CEO, effective November 1, 2016. Bernhard Günther – the former CEO – will commence the new role of Chief Innovation Officer.
- Steven Schallhorn has been appointed Chief Medical Officer for Global Ophthalmic Devices at Carl Zeiss Meditech.
